Diagnosing and Understanding Tests
At a Glance
Chromosomal Microarray (CMA) is the gold standard diagnostic test for 22q11.2 deletion syndrome, as it detects exactly where the deletion starts and ends. Prenatal NIPT is only a screening test and requires postnatal confirmation.
Getting to a diagnosis of 22q11.2 deletion syndrome can be a journey. For some families, it happens before birth or shortly after; for others, it may take years of piecing together different health challenges [1]. Understanding the tools used to find the deletion can help you navigate medical records and advocate for the right care.
How the Diagnosis is Made
- Prenatal Screening: Non-Invasive Prenatal Testing (NIPT) or cell-free DNA (cfDNA) analyzes tiny pieces of fetal DNA found in the mother’s blood [2]. While very good at identifying risks, it is a screening test and requires confirmation [3].
- Chromosomal Microarray (CMA): This is the current gold standard diagnostic test [4]. It scans the entire genome at a very high resolution and tells doctors exactly where the deletion starts and ends [5][6].
- FISH (Fluorescence In Situ Hybridization): This is an older, targeted test [7]. It uses a glowing probe to see if a specific piece of Chromosome 22 is missing. While effective for “typical” cases, FISH can miss smaller deletions that a microarray would easily catch [4][8].
Overlapping Conditions and Misdiagnosis
22q11.2DS is often called “the great pretender” because its symptoms overlap with many other conditions [1].
- Overlapping Conditions: The syndrome is sometimes misdiagnosed as other genetic conditions like CHARGE Syndrome, which shares similar features such as heart defects and palate/ear issues. Doctors often test for multiple conditions to be sure [9].
- Isolated Findings: Sometimes a person is diagnosed with just an “isolated” heart defect or a “simple” speech delay, and the underlying genetic cause isn’t looked for until more symptoms appear in adulthood [10][11].
Reading Your Genetic Report
Your genetic pathology report is a critical piece of your medical history. A definitive report should include these key data points:
- Genomic Coordinates: The exact “map locations” on Chromosome 22 where the deletion begins and ends (e.g., chr22:18,912,231-21,465,672) [7][12].
- Deletion Size: Usually measured in megabases (Mb). A typical deletion is about 3 Mb, but some are smaller (1.5 Mb) [7][13].
- The Build: The version of the “human genome map” used for the test (often listed as Hg19 or Hg38) [7]. This helps doctors compare results accurately over time.
- Genes Involved: Confirmation that the TBX1 gene is included in the deleted area, as this gene drives many of the syndrome’s physical features [13][7].
Common questions in this guide
What is the best test to diagnose 22q11.2 deletion syndrome?
Can prenatal blood tests definitively diagnose the syndrome?
Why might a FISH test miss a 22q11.2 deletion?
What key information should be on my genetic pathology report?
Why is 22q11.2 deletion syndrome frequently misdiagnosed?
Related questions
Get notified when new evidence is published on 22q11.2 deletion syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (13)
- 1
22q11.2 deletion syndrome.
McDonald-McGinn DM, Sullivan KE, Marino B, et al.
Nature reviews. Disease primers 2015; (1()):15071 doi:10.1038/nrdp.2015.71.
PMID: 27189754 - 2
Performance of a targeted cell-free DNA prenatal test for 22q11.2 deletion in a large clinical cohort.
Bevilacqua E, Jani JC, Chaoui R, et al.
Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2021; (58(4)):597-602 doi:10.1002/uog.23699.
PMID: 34090308 - 3
Expanding the fetal phenotype: Prenatal sonographic findings and perinatal outcomes in a cohort of patients with a confirmed 22q11.2 deletion syndrome.
Schindewolf E, Khalek N, Johnson MP, et al.
American journal of medical genetics. Part A 2018; (176(8)):1735-1741 doi:10.1002/ajmg.a.38665.
PMID: 30055034 - 4
De Novo Interstitial Deletion of 9q in a Pediatric Patient With Global Developmental Delay.
Keselman D, Singh R, Cohen N, Fefer Z
Child neurology open 2019; (6()):2329048X19844920 doi:10.1177/2329048X19844920.
PMID: 31106228 - 5
Inverted duplication, triplication and quintuplication through sequential breakage-fusion-bridge events induced by a terminal deletion at 5p in a case of spontaneous abortion.
Chai H, Grommisch B, DiAdamo A, et al.
Molecular genetics & genomic medicine 2019; (7(10)):e00965 doi:10.1002/mgg3.965.
PMID: 31478360 - 6
Analytical and clinical performance of chromosomal microarrays compared with FISH panel and conventional karyotyping in patients with chronic lymphocytic leukemia.
Tang Z, Kanagal-Shamanna R, Tang G, et al.
Leukemia research 2021; (108()):106616 doi:10.1016/j.leukres.2021.106616.
PMID: 34022744 - 7
22q and two: 22q11.2 deletion syndrome and coexisting conditions.
Cohen JL, Crowley TB, McGinn DE, et al.
American journal of medical genetics. Part A 2018; (176(10)):2203-2214 doi:10.1002/ajmg.a.40494.
PMID: 30244528 - 8
Improved assay performance of single nucleotide polymorphism array over conventional karyotyping in analyzing products of conception.
Lin SB, Xie YJ, Chen Z, et al.
Journal of the Chinese Medical Association : JCMA 2015; (78(7)):408-13.
PMID: 26004737 - 9
Cardiovascular Malformations in CHARGE Syndrome with DiGeorge Phenotype: Two Case Reports.
Yasuda K, Morihana E, Fusazaki N, Ishikawa S
Case reports in pediatrics 2016; (2016()):8013530 doi:10.1155/2016/8013530.
PMID: 27957375 - 10
Aortic Arch Laterality in Chromosome 22q11.2 Deletion Syndrome: Male-Female Difference.
Evans WN, Acherman RJ, Restrepo H
Clinical pediatrics 2023; (62(4)):345-348 doi:10.1177/00099228221127730.
PMID: 36214167 - 11
Prevalence of chromosomal abnormalities and 22q11.2 deletion in conotruncal and non-conotruncal antenatally diagnosed congenital heart diseases in a Chinese population.
Kong CW, Cheng YKY, To WWK, Leung TY
Hong Kong medical journal = Xianggang yi xue za zhi 2019; (25(1)):6-12 doi:10.12809/hkmj187552.
PMID: 30655461 - 12
Chromosome 22q11.2 Deletion Syndrome: A Comprehensive Review of Molecular Genetics in the Context of Multidisciplinary Clinical Approach.
Szczawińska-Popłonyk A, Schwartzmann E, Chmara Z, et al.
International journal of molecular sciences 2023; (24(9)) doi:10.3390/ijms24098317.
PMID: 37176024 - 13
The 22q11.2 deletion syndrome: Genetic mechanisms, clinical manifestations, and therapeutic strategies.
Yang S, Zhuang Y, Xin S, et al.
Clinica chimica acta; international journal of clinical chemistry 2026; (586()):120893 doi:10.1016/j.cca.2026.120893.
PMID: 41690495
This page provides educational information about genetic testing for 22q11.2 deletion syndrome. Always review your specific genetic pathology report and test results with a qualified genetic counselor or medical geneticist.